140 0 3 0 3 O
- 4 5 4 5 O
age 6 9 6 9 B-age
in 10 12 10 12 O
years 13 18 13 18 O
} 18 19 18 19 O
× 20 21 20 21 O
{ 22 23 22 23 O
actual 23 29 23 29 O
weight 30 36 30 36 B-clinical_variable
in 37 39 37 39 O
kg 40 42 40 42 O
} 42 43 42 43 O
] 43 44 43 44 O
divided 45 52 45 52 O
by 53 55 53 55 O
[ 56 57 56 57 O
{ 57 58 57 58 O
72 58 60 58 60 O
× 61 62 61 62 O
serum 63 68 63 68 B-clinical_variable
creatinine 69 79 69 79 I-clinical_variable
in 80 82 80 82 O
mg 83 85 83 85 O
/ 85 86 85 86 O
dL 86 88 86 88 O
} 88 89 88 89 O
multiply 90 98 90 98 O
by 99 101 99 101 O
0.85 102 106 102 106 O
if 107 109 107 109 O
female 110 116 110 116 B-gender
] 116 117 116 117 O
) 117 118 117 118 O
, 118 119 118 119 O
OR 120 122 120 122 O
creatinine 123 133 123 133 O
= 134 135 134 135 O
< 135 136 135 136 O
1.5 137 140 137 140 B-upper_bound
x 141 142 141 142 I-upper_bound
ULN 143 146 143 146 I-upper_bound

= 0 1 147 148 O
< 1 2 148 149 O
1.5 3 6 150 153 B-upper_bound
x 7 8 154 155 I-upper_bound
ULN 9 12 156 159 I-upper_bound

> 0 1 160 161 O
470 2 5 162 165 B-lower_bound
ms 6 8 166 168 I-lower_bound
for 9 12 169 172 O
females 13 20 173 180 B-gender
based 21 26 181 186 O
on 27 29 187 189 O
triplicate 30 40 190 200 O
ECG 41 44 201 204 B-treatment

> 0 1 205 206 O
= 1 2 206 207 O
18 3 5 208 210 B-lower_bound
years 6 11 211 216 I-lower_bound
old 12 15 217 220 O

A 0 1 221 222 O
minimum 2 9 223 230 O
of 10 12 231 233 O
4 13 14 234 235 B-lower_bound
weeks 15 20 236 241 I-lower_bound
must 21 25 242 246 O
have 26 30 247 251 O
elapsed 31 38 252 259 O
between 39 46 260 267 O
the 47 50 268 271 O
end 51 54 272 275 O
of 55 57 276 278 O
whole 58 63 279 284 O
brain 64 69 285 290 B-treatment
radiotherapy 70 82 291 303 I-treatment
and 83 86 304 307 O
study 87 92 308 313 O
enrollment 93 103 314 324 O
( 104 105 325 326 O
2 105 106 326 327 B-lower_bound
weeks 107 112 328 333 I-lower_bound
for 113 116 334 337 O
stereotactic 117 129 338 350 B-treatment
radiotherapy 130 142 351 363 I-treatment
) 142 143 363 364 O

AST 0 3 365 368 B-clinical_variable
/ 3 4 368 369 I-clinical_variable
ALT 4 7 369 372 I-clinical_variable
levels 8 14 373 379 I-clinical_variable
= 15 16 380 381 O
< 16 17 381 382 O
3 18 19 383 384 B-upper_bound
x 20 21 385 386 I-upper_bound
ULN 22 25 387 390 I-upper_bound

Bilirubin 0 9 391 400 B-clinical_variable
= 10 11 401 402 O
< 11 12 402 403 O
1.5 13 16 404 407 B-upper_bound
x 17 18 408 409 I-upper_bound
ULN 19 22 410 413 I-upper_bound

Confirmation 0 12 414 426 O
of 13 15 427 429 O
TP53 16 20 430 434 O
nonmutant 21 30 435 444 O
status 31 37 445 451 O
is 38 40 452 454 O
encouraged 41 51 455 465 O
, 51 52 465 466 O
but 53 56 467 470 O
not 57 60 471 474 O
required 61 69 475 483 O
prior 70 75 484 489 O
to 76 78 490 492 O
DS-3032b 79 87 493 501 B-treatment
dosing 88 94 502 508 O

Creatinine 0 10 509 519 B-clinical_variable
clearance 11 20 520 529 I-clinical_variable
> 21 22 530 531 O
= 22 23 531 532 O
60 24 26 533 535 B-lower_bound
mL 27 29 536 538 I-lower_bound
/ 29 30 538 539 I-lower_bound
min 30 33 539 542 I-lower_bound

Had 0 3 543 546 O
an 4 6 547 549 O
autologous 7 17 550 560 B-treatment
transplant 18 28 561 571 I-treatment
within 29 35 572 578 O
3 36 37 579 580 B-upper_bound
months 38 44 581 587 I-upper_bound
of 45 47 588 590 O
starting 48 56 591 599 O
study 57 62 600 605 B-treatment
drug 63 67 606 610 I-treatment
treatment 68 77 611 620 I-treatment

Had 0 3 621 624 O
systemic 4 12 625 633 B-treatment
treatment 13 22 634 643 I-treatment
with 23 27 644 648 O
anticancer 28 38 649 659 B-treatment
therapy 39 46 660 667 I-treatment
, 46 47 667 668 O
antibody 48 56 669 677 B-treatment
- 56 57 677 678 I-treatment
based 57 62 678 683 I-treatment
therapy 63 70 684 691 I-treatment
, 70 71 691 692 O
retinoid 72 80 693 701 B-treatment
therapy 81 88 702 709 I-treatment
, 88 89 709 710 O
or 90 92 711 713 O
hormonal 93 101 714 722 B-treatment
therapy 102 109 723 730 I-treatment

Had 0 3 731 734 O
therapeutic 4 15 735 746 B-treatment
radiation 16 25 747 756 I-treatment
therapy 26 33 757 764 I-treatment
or 34 36 765 767 O
major 37 42 768 773 B-treatment
surgery 43 50 774 781 I-treatment
within 51 57 782 788 O
4 58 59 789 790 B-upper_bound
weeks 60 65 791 796 I-upper_bound
before 66 72 797 803 O
study 73 78 804 809 B-treatment
drug 79 83 810 814 I-treatment
treatment 84 93 815 824 I-treatment

Has 0 3 825 828 O
a 4 5 829 830 O
histologically 6 20 831 845 O
or 21 23 846 848 O
cytologically 24 37 849 862 O
documented 38 48 863 873 O
advanced 49 57 874 882 O
solid 58 63 883 888 B-cancer
tumor 64 69 889 894 I-cancer
or 70 72 895 897 O
lymphoma 73 81 898 906 B-cancer
that 82 86 907 911 O
has 87 90 912 915 O
relapsed 91 99 916 924 O
from 100 104 925 929 O
or 105 107 930 932 O
is 108 110 933 935 O
refractory 111 121 936 946 O
to 122 124 947 949 O
standard 125 133 950 958 B-treatment
treatment 134 143 959 968 I-treatment

Has 0 3 969 972 O
a 4 5 973 974 O
history 6 13 975 982 O
of 14 16 983 985 O
primary 17 24 986 993 B-cancer
central 25 32 994 1001 I-cancer
nervous 33 40 1002 1009 I-cancer
system 41 47 1010 1016 I-cancer
malignancy 48 58 1017 1027 I-cancer

Has 0 3 1028 1031 O
a 4 5 1032 1033 O
tumor 6 11 1034 1039 B-cancer
that 12 16 1040 1044 O
contains 17 25 1045 1053 O
a 26 27 1054 1055 O
nonsynonymous 28 41 1056 1069 B-treatment
mutation 42 50 1070 1078 I-treatment
, 50 51 1078 1079 O
insertion 52 61 1080 1089 O
, 61 62 1089 1090 O
or 63 65 1091 1093 O
deletion 66 74 1094 1102 O
in 75 77 1103 1105 O
the 78 81 1106 1109 O
TP53 82 86 1110 1114 B-clinical_variable
gene 87 91 1115 1119 I-clinical_variable
determined 92 102 1120 1130 O
previously 103 113 1131 1141 O
or 114 116 1142 1144 O
at 117 119 1145 1147 O
screening 120 129 1148 1157 O

Has 0 3 1158 1161 O
an 4 6 1162 1164 O
Eastern 7 14 1165 1172 B-clinical_variable
Cooperative 15 26 1173 1184 I-clinical_variable
Oncology 27 35 1185 1193 I-clinical_variable
Group 36 41 1194 1199 I-clinical_variable
( 42 43 1200 1201 I-clinical_variable
ECOG 43 47 1201 1205 I-clinical_variable
) 47 48 1205 1206 I-clinical_variable
performance 49 60 1207 1218 I-clinical_variable
status 61 67 1219 1225 I-clinical_variable
0 68 69 1226 1227 B-lower_bound
- 69 70 1227 1228 O
1 70 71 1228 1229 B-upper_bound

Has 0 3 1230 1233 O
clinically 4 14 1234 1244 O
active 15 21 1245 1251 O
brain 22 27 1252 1257 B-cancer
metastases 28 38 1258 1268 I-cancer
, 38 39 1268 1269 O
defined 40 47 1270 1277 O
as 48 50 1278 1280 O
untreated 51 60 1281 1290 O
and 61 64 1291 1294 O
symptomatic 65 76 1295 1306 O
, 76 77 1306 1307 O
or 78 80 1308 1310 O
requiring 81 90 1311 1320 O
therapy 91 98 1321 1328 B-treatment
with 99 103 1329 1333 O
steroids 104 112 1334 1342 B-treatment
or 113 115 1343 1345 O
anticonvulsants 116 131 1346 1361 B-treatment
to 132 134 1362 1364 O
control 135 142 1365 1372 O
associated 143 153 1373 1383 O
symptoms 154 162 1384 1392 O

Has 0 3 1393 1396 O
gastrointestinal 4 20 1397 1413 B-chronic_disease
conditions 21 31 1414 1424 I-chronic_disease
that 32 36 1425 1429 O
could 37 42 1430 1435 O
affect 43 49 1436 1442 O
the 50 53 1443 1446 O
absorption 54 64 1447 1457 O
of 65 67 1458 1460 O
DS-3032b 68 76 1461 1469 B-treatment
in 77 79 1470 1472 O
the 80 83 1473 1476 O
opinion 84 91 1477 1484 O
of 92 94 1485 1487 O
the 95 98 1488 1491 O
Investigator 99 111 1492 1504 O

Has 0 3 1505 1508 O
received 4 12 1509 1517 O
an 13 15 1518 1520 O
allogeneic 16 26 1521 1531 B-treatment
bone 27 31 1532 1536 I-treatment
marrow 32 38 1537 1543 I-treatment
or 39 41 1544 1546 O
allogeneic 42 52 1547 1557 B-treatment
stem 53 57 1558 1562 I-treatment
cell 58 62 1563 1567 I-treatment
transplant 63 73 1568 1578 I-treatment

Has 0 3 1579 1582 O
unresolved 4 14 1583 1593 O
toxicities 15 25 1594 1604 O
from 26 30 1605 1609 O
previous 31 39 1610 1618 B-treatment
anticancer 40 50 1619 1629 I-treatment
therapy 51 58 1630 1637 I-treatment
, 58 59 1637 1638 O
defined 60 67 1639 1646 O
as 68 70 1647 1649 O
toxicities 71 81 1650 1660 O
( 82 83 1661 1662 O
other 83 88 1662 1667 O
than 89 93 1668 1672 O
alopecia 94 102 1673 1681 B-chronic_disease
) 102 103 1681 1682 O
not 104 107 1683 1686 O
yet 108 111 1687 1690 O
resolved 112 120 1691 1699 O
to 121 123 1700 1702 O
NCI 124 127 1703 1706 O
- 127 128 1706 1707 O
CTCAE 128 133 1707 1712 O
v4 134 136 1713 1715 O

International 0 13 1716 1729 B-clinical_variable
normalized 14 24 1730 1740 I-clinical_variable
ratio 25 30 1741 1746 I-clinical_variable
( 31 32 1747 1748 I-clinical_variable
INR 32 35 1748 1751 I-clinical_variable
) 35 36 1751 1752 I-clinical_variable
and 37 40 1753 1756 O
activated 41 50 1757 1766 B-clinical_variable
partial 51 58 1767 1774 I-clinical_variable
thromboplastin 59 73 1775 1789 I-clinical_variable
time 74 78 1790 1794 I-clinical_variable
( 79 80 1795 1796 I-clinical_variable
aPTT 80 84 1796 1800 I-clinical_variable
) 84 85 1800 1801 I-clinical_variable

Is 0 2 1802 1804 O
receiving 3 12 1805 1814 O
concomitant 13 24 1815 1826 B-treatment
treatment 25 34 1827 1836 I-treatment
with 35 39 1837 1841 I-treatment
a 40 41 1842 1843 I-treatment
strong 42 48 1844 1850 I-treatment
inhibitor 49 58 1851 1860 I-treatment
or 59 61 1861 1863 I-treatment
inducer 62 69 1864 1871 I-treatment
of 70 72 1872 1874 I-treatment
CYP3A4/5 73 81 1875 1883 I-treatment

Is 0 2 1884 1886 O
willing 3 10 1887 1894 O
to 11 13 1895 1897 O
provide 14 21 1898 1905 O
and 22 25 1906 1909 O
there 26 31 1910 1915 O
is 32 34 1916 1918 O
confirmed 35 44 1919 1928 O
availability 45 57 1929 1941 O
of 58 60 1942 1944 O
pre 61 64 1945 1948 O
- 64 65 1948 1949 O
existing 65 73 1949 1957 O
diagnostic 74 84 1958 1968 O
or 85 87 1969 1971 O
resected 88 96 1972 1980 O
tumor 97 102 1981 1986 B-cancer
samples 103 110 1987 1994 O
, 110 111 1994 1995 O
such 112 116 1996 2000 O
as 117 119 2001 2003 O
paraffin 120 128 2004 2012 B-treatment
- 128 129 2012 2013 O
embedded 129 137 2013 2021 O
sections 138 146 2022 2030 O

Is 0 2 2031 2033 O
willing 3 10 2034 2041 O
to 11 13 2042 2044 O
undergo 14 21 2045 2052 O
tumor 22 27 2053 2058 B-treatment
genotyping 28 38 2059 2069 I-treatment
for 39 42 2070 2073 O
TP53 43 47 2074 2078 O
mutation 48 56 2079 2087 O
, 56 57 2087 2088 O
insertion 58 67 2089 2098 O
, 67 68 2098 2099 O
or 69 71 2100 2102 O
deletion 72 80 2103 2111 O
at 81 83 2112 2114 O
screening 84 93 2115 2124 O

Man 0 3 2125 2128 B-gender

Participated 0 12 2129 2141 O
in 13 15 2142 2144 O
a 16 17 2145 2146 O
therapeutic 18 29 2147 2158 B-treatment
clinical 30 38 2159 2167 I-treatment
study 39 44 2168 2173 I-treatment
within 45 51 2174 2180 O
3 52 53 2181 2182 B-upper_bound
weeks 54 59 2183 2188 I-upper_bound
before 60 66 2189 2195 I-upper_bound
study 67 72 2196 2201 B-treatment
drug 73 77 2202 2206 I-treatment
treatment 78 87 2207 2216 I-treatment

Platelet 0 8 2217 2225 B-clinical_variable
count 9 14 2226 2231 I-clinical_variable
> 15 16 2232 2233 O
= 16 17 2233 2234 O
100 18 21 2235 2238 B-lower_bound
x 22 23 2239 2240 I-lower_bound
109 24 27 2241 2244 I-lower_bound
/ 27 28 2244 2245 I-lower_bound
L 28 29 2245 2246 I-lower_bound
Hemoglobin 30 40 2247 2257 B-clinical_variable
> 41 42 2258 2259 O
= 42 43 2259 2260 O
9.0 44 47 2261 2264 B-lower_bound
g 48 49 2265 2266 I-lower_bound
/ 49 50 2266 2267 I-lower_bound
dL 50 52 2267 2269 I-lower_bound
Absolute 53 61 2270 2278 B-clinical_variable
neutrophil 62 72 2279 2289 I-clinical_variable
count 73 78 2290 2295 I-clinical_variable
> 79 80 2296 2297 O
= 80 81 2297 2298 O
1.5 82 85 2299 2302 B-lower_bound
x 86 87 2303 2304 I-lower_bound
109 88 91 2305 2308 I-lower_bound
/ 91 92 2308 2309 I-lower_bound
L 92 93 2309 2310 I-lower_bound

Pregnant 0 8 2311 2319 B-pregnancy

Prior 0 5 2320 2325 O
treatment 6 15 2326 2335 B-treatment
with 16 20 2336 2340 O
an 21 23 2341 2343 O
MDM2 24 28 2344 2348 B-treatment
inhibitor 29 38 2349 2358 I-treatment

Prolongation 0 12 2359 2371 O
of 13 15 2372 2374 O
corrected 16 25 2375 2384 B-clinical_variable
QT 26 28 2385 2387 I-clinical_variable
interval 29 37 2388 2396 I-clinical_variable
by 38 40 2397 2399 I-clinical_variable
Fridericia 41 51 2400 2410 I-clinical_variable
's 51 53 2410 2412 I-clinical_variable
method 54 60 2413 2419 I-clinical_variable
( 61 62 2420 2421 I-clinical_variable
QTcF 62 66 2421 2425 I-clinical_variable
) 66 67 2425 2426 I-clinical_variable
at 68 70 2427 2429 O
rest 71 75 2430 2434 O
, 75 76 2434 2435 O
where 77 82 2436 2441 O
the 83 86 2442 2445 O
mean 87 91 2446 2450 O
QTcF 92 96 2451 2455 B-clinical_variable
interval 97 105 2456 2464 I-clinical_variable
is 106 108 2465 2467 O
> 109 110 2468 2469 O
450 111 114 2470 2473 B-lower_bound
milliseconds 115 127 2474 2486 I-lower_bound
( 128 129 2487 2488 I-lower_bound
ms 129 131 2488 2490 I-lower_bound
) 131 132 2490 2491 I-lower_bound
for 133 136 2492 2495 O
males 137 142 2496 2501 B-gender

Providing 0 9 2502 2511 O
fresh 10 15 2512 2517 O
tumor 16 21 2518 2523 O
biopsy 22 28 2524 2530 B-treatment
is 29 31 2531 2533 O
optional 32 40 2534 2542 O
for 41 44 2543 2546 O
subjects 45 53 2547 2555 O
in 54 56 2556 2558 O
Dose 57 61 2559 2563 O
Escalation 62 72 2564 2574 O
cohorts 73 80 2575 2582 O

Subject 0 7 2583 2590 O
( 8 9 2591 2592 O
male 9 13 2592 2596 B-gender
and 14 17 2597 2600 I-gender
female 18 24 2601 2607 I-gender
) 24 25 2607 2608 O
of 26 28 2609 2611 O
childbearing 29 41 2612 2624 O
/ 41 42 2624 2625 O
reproductive 42 54 2625 2637 O
potential 55 64 2638 2647 O
must 65 69 2648 2652 O
agree 70 75 2653 2658 B-contraception_consent
to 76 78 2659 2661 I-contraception_consent
use 79 82 2662 2665 I-contraception_consent
double 83 89 2666 2672 I-contraception_consent
- 89 90 2672 2673 I-contraception_consent
barrier 90 97 2673 2680 I-contraception_consent
contraceptive 98 111 2681 2694 I-contraception_consent
measures 112 120 2695 2703 O
or 121 123 2704 2706 O
avoid 124 129 2707 2712 O
intercourse 130 141 2713 2724 O
during 142 148 2725 2731 O
the 149 152 2732 2735 O
study 153 158 2736 2741 O

Subject 0 7 2742 2749 O
should 8 14 2750 2756 O
be 15 17 2757 2759 O
able 18 22 2760 2764 O
to 23 25 2765 2767 O
provide 26 33 2768 2775 O
written 34 41 2776 2783 O
informed 42 50 2784 2792 O
consent 51 58 2793 2800 O
, 58 59 2800 2801 O
comply 60 66 2802 2808 O
with 67 71 2809 2813 O
protocol 72 80 2814 2822 O
visits 81 87 2823 2829 O
and 88 91 2830 2833 O
procedures 92 102 2834 2844 O
, 102 103 2844 2845 O
be 104 106 2846 2848 O
able 107 111 2849 2853 O
to 112 114 2854 2856 O
take 115 119 2857 2861 O
oral 120 124 2862 2866 B-treatment
medication 125 135 2867 2877 I-treatment
, 135 136 2877 2878 O
and 137 140 2879 2882 O
not 141 144 2883 2886 O
have 145 149 2887 2891 O
any 150 153 2892 2895 O
active 154 160 2896 2902 B-chronic_disease
infection 161 170 2903 2912 I-chronic_disease
or 171 173 2913 2915 O
comorbidity 174 185 2916 2927 O
that 186 190 2928 2932 O
would 191 196 2933 2938 O
interfere 197 206 2939 2948 O
with 207 211 2949 2953 O
therapy 212 219 2954 2961 B-treatment

Subjects 0 8 2962 2970 O
with 9 13 2971 2975 O
chronic 14 21 2976 2983 O
grade 22 27 2984 2989 B-chronic_disease
2 28 29 2990 2991 I-chronic_disease
toxicities 30 40 2992 3002 I-chronic_disease
may 41 44 3003 3006 O
be 45 47 3007 3009 O
eligible 48 56 3010 3018 O
per 57 60 3019 3022 O
the 61 64 3023 3026 O
discretion 65 75 3027 3037 O
of 76 78 3038 3040 O
the 79 82 3041 3044 O
Investigator 83 95 3045 3057 O
and 96 99 3058 3061 O
Sponsor 100 107 3062 3069 O
( 108 109 3070 3071 O
eg 109 111 3071 3073 O
, 111 112 3073 3074 O
grade 113 118 3075 3080 B-treatment
2 119 120 3081 3082 I-treatment
chemotherapy 121 133 3083 3095 I-treatment
- 133 134 3095 3096 I-treatment
induced 134 141 3096 3103 I-treatment
neuropathy 142 152 3104 3114 I-treatment
) 152 153 3114 3115 O

Subjects 0 8 3116 3124 O
with 9 13 3125 3129 O
melanoma 14 22 3130 3138 B-cancer
who 23 26 3139 3142 O
are 27 30 3143 3146 O
ineligible 31 41 3147 3157 O
to 42 44 3158 3160 O
receive 45 52 3161 3168 O
or 53 55 3169 3171 O
have 56 60 3172 3176 O
declined 61 69 3177 3185 O
ipilimumab 70 80 3186 3196 B-treatment
treatment 81 90 3197 3206 I-treatment
, 90 91 3206 3207 O
or 92 94 3208 3210 O
who 95 98 3211 3214 O
are 99 102 3215 3218 O
refractory 103 113 3219 3229 O
or 114 116 3230 3232 O
intolerant 117 127 3233 3243 O
to 128 130 3244 3246 O
ipilimumab 131 141 3247 3257 O
may 142 145 3258 3261 O
enroll 146 152 3262 3268 O

Substance 0 9 3269 3278 O
abuse 10 15 3279 3284 O
or 16 18 3285 3287 O
medical 19 26 3288 3295 B-chronic_disease
, 26 27 3295 3296 O
psychological 28 41 3297 3310 B-chronic_disease
, 41 42 3310 3311 O
or 43 45 3312 3314 O
social 46 52 3315 3321 O
conditions 53 63 3322 3332 O
that 64 68 3333 3337 O
, 68 69 3337 3338 O
in 70 72 3339 3341 O
the 73 76 3342 3345 O
opinion 77 84 3346 3353 O
of 85 87 3354 3356 O
the 88 91 3357 3360 O
Investigator 92 104 3361 3373 O
, 104 105 3373 3374 O
may 106 109 3375 3378 O
interfere 110 119 3379 3388 O
with 120 124 3389 3393 O
the 125 128 3394 3397 O
subject 129 136 3398 3405 O
's 136 138 3405 3407 O
participation 139 152 3408 3421 O
in 153 155 3422 3424 O
the 156 159 3425 3428 O
clinical 160 168 3429 3437 O
study 169 174 3438 3443 O
or 175 177 3444 3446 O
evaluation 178 188 3447 3457 O
of 189 191 3458 3460 O
the 192 195 3461 3464 O
clinical 196 204 3465 3473 O
study 205 210 3474 3479 O
results 211 218 3480 3487 O

current 0 7 3488 3495 O
participation 8 21 3496 3509 O
in 22 24 3510 3512 O
other 25 30 3513 3518 O
therapeutic 31 42 3519 3530 B-treatment
investigational 43 58 3531 3546 I-treatment
procedures 59 69 3547 3557 O

for 0 3 3558 3561 O
90 4 6 3562 3564 B-upper_bound
days 7 11 3565 3569 I-upper_bound
after 12 17 3570 3575 I-upper_bound
the 18 21 3576 3579 O
last 22 26 3580 3584 O
dose 27 31 3585 3589 O
of 32 34 3590 3592 O
study 35 40 3593 3598 O
drug 41 45 3599 3603 O

for 0 3 3604 3607 O
which 4 9 3608 3613 O
no 10 12 3614 3616 O
standard 13 21 3617 3625 O
treatment 22 31 3626 3635 B-treatment
is 32 34 3636 3638 O
available 35 44 3639 3648 O

grade 0 5 3649 3654 B-clinical_variable
= 6 7 3655 3656 O
< 7 8 3656 3657 O
1 9 10 3658 3659 B-upper_bound
or 11 13 3660 3662 O
baseline 14 22 3663 3671 O

palliative 0 10 3672 3682 B-treatment
radiation 11 20 3683 3692 I-treatment
therapy 21 28 3693 3700 I-treatment
within 29 35 3701 3707 O
2 36 37 3708 3709 B-upper_bound
weeks 38 43 3710 3715 I-upper_bound
before 44 50 3716 3722 O
study 51 56 3723 3728 O
drug 57 61 3729 3733 O
treatment 62 71 3734 3743 B-treatment

treatment 0 9 3744 3753 B-treatment
with 10 14 3754 3758 I-treatment
nitrosoureas 15 27 3759 3771 I-treatment
or 28 30 3772 3774 O
mitomycin 31 40 3775 3784 B-treatment
C 41 42 3785 3786 I-treatment
within 43 49 3787 3793 O
6 50 51 3794 3795 B-upper_bound
weeks 52 57 3796 3801 I-upper_bound
before 58 64 3802 3808 O
study 65 70 3809 3814 O
drug 71 75 3815 3819 B-treatment
treatment 76 85 3820 3829 I-treatment

treatment 0 9 3830 3839 B-treatment
with 10 14 3840 3844 O
small 15 20 3845 3850 O
- 20 21 3850 3851 O
molecule 21 29 3851 3859 O
targeted 30 38 3860 3868 O
agents 39 45 3869 3875 O
within 46 52 3876 3882 O
2 53 54 3883 3884 B-upper_bound
weeks 55 60 3885 3890 I-upper_bound
before 61 67 3891 3897 O
study 68 73 3898 3903 O
drug 74 78 3904 3908 O
treatment 79 88 3909 3918 O

within 0 6 3919 3925 O
3 7 8 3926 3927 B-upper_bound
weeks 9 14 3928 3933 I-upper_bound
before 15 21 3934 3940 O
study 22 27 3941 3946 O
drug 28 32 3947 3951 B-treatment
treatment 33 42 3952 3961 I-treatment

woman 0 5 3962 3967 B-gender

